Stefan Scherer
Chief Executive Officer & President 3T Biosciences
Seminars
Wednesday 20th May 2026
Guiding TCR Therapies from Discovery to Dosing Using End-to-End Platform Insights
4:00 pm
- Conducting MABEL calculations and safety studies in organoids to guide dosing
- Characterizing clinical performance early to strengthen development decisions
- Leveraging the end-to-end benefits of a target discovery platform to derisk your product
